Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

The awards carry four-year vesting schedules, with continued employee service required through the applicable vesting dates.

Rhea-AI Summary

Vera Therapeutics (VERA) granted stock options and restricted stock units to five new employees on September 29, 2026.

The inducement awards cover options to purchase 16,700 Class A shares and restricted stock units (RSUs) underlying 8,350 Class A shares. The options have a $32.38 exercise price, equal to the closing trading price on the grant date. Options vest over four years: 25% on the first anniversary of the applicable vesting commencement date, then monthly over 36 months. RSUs vest over four years, with 25% on each anniversary of November 20. Both require continued service through the applicable vesting dates. The Compensation Committee approved the grants under the Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Positive

• None.

Negative

• Minor point. Forward-looking: it has not happened yet and may not happen.16,700 stock options at a $32.38 exercise price create potential dilution as they vest and are exercised.
• Minor point. Forward-looking: it has not happened yet and may not happen.RSUs underlying 8,350 Class A shares create potential dilution as the awards vest.

News Explained

The grants create potential—not immediate—share dilution: options cover 16,700 shares and RSUs another 8,350, with both award types subject to multi-year vesting and continued service.

Key Figures

Option awards: 16,700 shares RSU awards: 8,350 shares Employees receiving awards: 5 employees +3 more

Option awards

16,700 shares

Inducement grants to new employees

RSU awards

8,350 shares

Inducement grants to new employees

Employees receiving awards

5 employees

New employees under the Inducement Plan

Option exercise price

$32.38 per share

Options granted September 29, 2026

Option vesting

4 years; 25% at the first anniversary, remainder monthly over 36 months

Subject to continued service

RSU vesting

4 years; 25% on each anniversary of November 20

Subject to continued service

Key Terms

non-qualified stock options, restricted stock units, nasdaq listing rule 5635(c)(4)

3 terms

non-qualified stock options financial

"inducement awards consisting of non-qualified stock options"

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"and restricted stock units (RSUs) underlying"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on September 29, 2026, the Compensation Committee of the Board of Directors (Compensation Committee) of Vera Therapeutics granted inducement awards consisting of non-qualified stock options to purchase 16,700 shares of Class A common stock and restricted stock units (RSUs) underlying 8,350 shares of Class A common stock to five (5) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option granted on September 29, 2026 has an exercise price per share equal to $32.38, Vera Therapeutics’ closing trading price on September 29, 2026. Each stock option will vest over four years, with 25% of the underlying shares vesting on the first anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. Each of the RSU awards will vest over four years, with 25% of the underlying shares vesting on each anniversary of November 20, subject to the new employee’s continued service relationship with Vera Therapeutics through the applicable vesting dates. The awards are subject to the terms and conditions of the Inducement Plan and the terms and conditions of an applicable award agreement covering the grant.

About Vera Therapeutics
Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA^™ (atacicept-vymj), a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor. Vera Therapeutics is evaluating multiple diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

For more information, please contact:

Investor Contact:
Joshua Qin
Vera Therapeutics 650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth Vera Therapeutics 415-854-8051
corporatecommunications@veratx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What inducement awards did Vera Therapeutics grant to new employees?

Vera Therapeutics granted five new employees options to purchase 16,700 Class A shares and RSUs underlying 8,350 Class A shares on September 29, 2026. The options have an exercise price of $32.38 per share, equal to the closing trading price that day.

When do Vera Therapeutics' September 29, 2026 inducement awards vest?

Both award types vest over four years, subject to continued service through the applicable vesting dates. Options vest 25% on the first anniversary of the applicable vesting commencement date, with the balance vesting monthly over 36 months. RSUs vest 25% on each anniversary of November 20.